OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
IPO Year: 2017
Exchange: NASDAQ
Website: orthopediatrics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/7/2025 | $37.00 | Buy | Lake Street |
| 1/25/2024 | $39.00 → $31.00 | Buy → Hold | Truist |
| 3/3/2022 | $83.00 → $65.00 | Buy | Needham |
| 12/22/2021 | $75.00 → $68.00 | Buy | BTIG |
| 12/21/2021 | $78.00 → $75.00 | Buy | Truist Securities |
| 8/6/2021 | $70.00 → $77.00 | Market Outperform | JMP Securities |
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
4 - ORTHOPEDIATRICS CORP (0001425450) (Issuer)
Lake Street initiated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $37.00
Truist downgraded OrthoPediatrics from Buy to Hold and set a new price target of $31.00 from $39.00 previously
Needham reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $65.00 from $83.00 previously
BTIG reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $68.00 from $75.00 previously
Truist Securities reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $75.00 from $78.00 previously
JMP Securities reiterated coverage of OrthoPediatrics with a rating of Market Outperform and set a new price target of $77.00 from $70.00 previously
Needham reiterated coverage of OrthoPediatrics with a rating of Buy and set a new price target of $77.00 from $70.00 previously
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
SCHEDULE 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SCHEDULE 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
10-Q - ORTHOPEDIATRICS CORP (0001425450) (Filer)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
8-K - ORTHOPEDIATRICS CORP (0001425450) (Filer)
DEFR14A - ORTHOPEDIATRICS CORP (0001425450) (Filer)
DEFA14A - ORTHOPEDIATRICS CORP (0001425450) (Filer)
DEF 14A - ORTHOPEDIATRICS CORP (0001425450) (Filer)
WARSAW, Ind., May 14, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its continued support of the 2025 Pediatric Orthopaedic Society of North America ("POSNA") annual meeting as an Emerald Sponsor. At the Annual Meeting, the Company will highlight its growing portfolio of pediatric-specific solutions, including OrthoPediatrics Specialty Bracing ("OPSB") and Enabling Technologies, at its three exhibit booths. OrthoPediatrics has established a long-term commitment to POSNA providing ongoing support of specialty symposiums and awarding educational
WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Business Highlights Helped a record of nearly 39,000 children in the first quarter of 2025Generated total revenue of $52.4 million for the first quarter of 2025, up 17% from $44.7 million in first quarter 2024; domestic revenue increased 19% and international revenue increased 11% in the quarterGrew worldwide Trauma & Deformity revenue 14% and worldwide Scoliosis revenue 34% in the first
WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and Deformity portfolio with 3P™ Pediatric Plating Platform™ Hip System, the first of several systems in the 3P family. This represents the company's 5th FDA approval in 2025. 3P Pediatric Plating Platform Hip System is a new plate and screw platform to modernize and revolutionize trauma and deformity correction treatment in the lower extremities. This family of plating systems will provide surgeons unparalleled coverage for a variety of Trauma and
WARSAW, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2025 financial results on May 7, 2025 after the market closes. OrthoPediatrics will host a conference call on Wednesday, May 7, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be available for repl
WARSAW, Ind., April 08, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the U.S. launch of the new VerteGlide Spinal Growth Guidance System, used to treat Early Onset Scoliosis ("EOS"). This represents the company's 80th system designed to treat musculoskeletal issues in children. VerteGlide is a guided growth technology designed for children with Early Onset Scoliosis, a severe and sometimes life-threatening condition affecting kids under the age of 10, who often suffer from pulmonary and digestive dysfunction because of the deformity. VerteG
WARSAW, Ind., March 25, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer, and Chief Financial Officer, are scheduled to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference. Event:24th Annual Needham Virtual Healthcare ConferenceFormat:Fireside ChatDate:Tuesday, April 8, 2025Time:9:30 am ET An audio webcast of the discussion will be available online at the OrthoPediatrics' investor relations website, http://ir.orthop
WARSAW, Ind., March 24, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it was selected as one of the 2025 Best Places to Work in Indiana. This is the 9th time the Company has been recognized by the annual program created by the Indiana Chamber of Commerce. OrthoPediatrics President & CEO David Bailey commented, "I'm so proud of our organization for being named one of the "Best Places to Work" in Indiana for a 9th time. Our leadership team is committed to fostering an engaging and inclusive culture, and meaningful career experiences for all our
WARSAW, Ind., March 17, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its partnership with the Crossroads Pediatric Device Consortium (CPDC). This collaboration aligns with the Company's cause of improving the lives of children by supporting the development and commercialization of innovative pediatric medical devices. The Crossroads Pediatric Device Consortium is a multi-institutional initiative focused on accelerating the development, approval, and availability of medical devices designed specifically for pediatric patients. Founding member
Record full year 2024 revenue of $204.7 million increased 38% compared to prior year, and more than doubled fourth quarter 2024 adjusted EBITDA WARSAW, Ind., March 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 & Recent Business Highlights Helped a new record of over 34,000 children in the fourth quarter 2024 and approximately 138,000 for full year 2024, bringing the total to over 1.14 million since the i
WARSAW, Ind., Feb. 19, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025 after the market closes. OrthoPediatrics will host a conference call on Tuesday, March 4, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13G/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13D/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
SC 13D/A - ORTHOPEDIATRICS CORP (0001425450) (Subject)
WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Business Highlights Helped a record of nearly 39,000 children in the first quarter of 2025Generated total revenue of $52.4 million for the first quarter of 2025, up 17% from $44.7 million in first quarter 2024; domestic revenue increased 19% and international revenue increased 11% in the quarterGrew worldwide Trauma & Deformity revenue 14% and worldwide Scoliosis revenue 34% in the first
WARSAW, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2025 financial results on May 7, 2025 after the market closes. OrthoPediatrics will host a conference call on Wednesday, May 7, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be available for repl
Record full year 2024 revenue of $204.7 million increased 38% compared to prior year, and more than doubled fourth quarter 2024 adjusted EBITDA WARSAW, Ind., March 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 & Recent Business Highlights Helped a new record of over 34,000 children in the fourth quarter 2024 and approximately 138,000 for full year 2024, bringing the total to over 1.14 million since the i
WARSAW, Ind., Feb. 19, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025 after the market closes. OrthoPediatrics will host a conference call on Tuesday, March 4, 2025 at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast
WARSAW, Ind., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2024. Third Quarter 2024 and Recent Business Highlights Helped a record of more than 33,000 children in the third quarter 2024, an increase of 50% from the third quarter 2023Generated record total revenue of $54.6 million for the third quarter of 2024, up 37% from $40.0 million in third quarter 2023; domestic revenue increased 45% and international revenue increased 12% in the quarterGrew w
WARSAW, Ind., Oct. 23, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its third quarter 2024 financial results on Wednesday, November 6, 2024, after the market closes. OrthoPediatrics will host a conference call on Thursday, November 7, 2024, at 8:00 a.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast
WARSAW, Ind., Aug. 05, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the second quarter ended June 30, 2024. Second Quarter 2024 and Recent Business Highlights Helped a record 32,000 children in the second quarter of 2024, an increase of 52% from the second quarter 2023Generated record total revenue of $52.8 million for the second quarter of 2024, up 33% from $39.6 million in second quarter 2023; domestic revenue increased 39% and international revenue increased 16% in the quarterGrew worldwide Trauma & Deformity
WARSAW, Ind., July 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its second quarter 2024 financial results on Monday, August 5, 2024, after the market closes. OrthoPediatrics will host a conference call on Tuesday, August 6, 2024, at 8:00 a.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be ava
WARSAW, Ind., May 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the first quarter ended March 31, 2024. First Quarter 2024 and Business Highlights Helped nearly 28,000 children in the first quarter of 2024, an increase of 47% from the first quarter 2023Generated total revenue of $44.7 million for the first quarter of 2024, up 41% from $31.6 million in first quarter 2023; domestic revenue increased 44% and international revenue increased 33% in the quarterGrew worldwide Trauma & Deformity revenue 42%, wo
WARSAW, Ind., April 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its first quarter 2024 financial results on Monday, May 6, 2024, after the market closes. OrthoPediatrics will host a conference call on Tuesday, May 7, 2024, at 8:00 a.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be available
WARSAW, Ind., March 17, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its partnership with the Crossroads Pediatric Device Consortium (CPDC). This collaboration aligns with the Company's cause of improving the lives of children by supporting the development and commercialization of innovative pediatric medical devices. The Crossroads Pediatric Device Consortium is a multi-institutional initiative focused on accelerating the development, approval, and availability of medical devices designed specifically for pediatric patients. Founding member
WARSAW, Ind., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, has announced a strategic partnership with Children's National Hospital in Washington, DC under the "Alliance for Pediatric Device Innovation" (APDI), to advice the development and commercialization of medical devices designed for children. Along with Children's National, APDI consortium members include Johns Hopkins University, CIMIT at Mass General Brigham, Tufts Medical Center and Medstar Health Research Institute. The Company will serve as APDI's strategic advisor and role model for devic
New CEO Paul Mraz also joins FzioMed Inc.'s Board of Directors; Company set to accelerate growth of market leading Oxiplex® adhesion barrier products. SAN LUIS OBISPO, Calif., Jan. 3, 2023 /PRNewswire/ -- FzioMed, Inc. ("FzioMed" or the "Company"), a global leading surgical biomaterials company focused on spine/orthopedic, peritoneal and gynecological surgery, today announced the appointment of industry veteran Paul Mraz as its new President and CEO and member of the Board of Directors. Mraz's appointment became effective Jan. 1, 2023, commensurate with the retirement of John Krelle who served in the leadership role since 2005. "On behalf of the Board of Directors, I want to thank John for
WARSAW, Ind., Oct. 20, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the appointment of Jimmy D. McDonald to its board of directors, effective October 18, 2022. Mark Throdahl, Executive Chairman of OrthoPediatrics' board said, "We are pleased to have attracted an Operations executive of Jimmy's stature to our company, which has an extensive supplier network of outsourced products. Beyond his directly relevant experience, Jimmy brings a wonderful personal fit with the culture of our board and our company." Mr. McDonald currently is Vice Pr
WARSAW, Ind., June 03, 2021 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics") (NASDAQ:KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the completion of the senior leadership transition, with David Bailey succeeding Mark Throdahl as Chief Executive Officer. Mark Throdahl will remain with the Company as Executive Chairman. "Over the last 10 years, it has been a privilege to work with our remarkable team leading the effort to improve the lives of children suffering from musculoskeletal disorders," said Mark Throdahl. "As Executive Chairman, I look forward to remaining highly engaged with OrthoPediatrics and its strategy as wel